MedTrace Logo

Lesinurad Tablet Bioequivalence

NCT02127775 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2014-09-22

No results posted yet for this study

Summary

This study will assess the bioequivalence of lesinurad tablets manufactured at two different sites.

Conditions

  • Healthy

Interventions

DRUG

Lesinurad 400 mg (manufactured at Site 1)

DRUG

Lesinurad 400 mg (manufactured at Site 2)

Sponsors & Collaborators

  • Ardea Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • J. Hall · Ardea Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-06-30
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02127775 on ClinicalTrials.gov